HAMP and lung cancer: There were no statistically significant differences in hepcidin, IL-6, and TNF-α concentrations between lung cancer subtypes or stages, as well as between patients with and without underlying lung diseases and other comorbidities such as type 2 diabetes mellitus and hypertension in female patients.